BioNTech's Ugur Sahin and Özlem Türeci after receiving the Federal Cross of Merit, March 19, 2021 (Bernd von Jutrczenka/picture-alliance/dpa/AP Images)
March 30, 2021 08:26 AM EDTUpdated 08:40 AM
Coronavirus

BioN­Tech makes a splash with $10B+ pro­jec­tion for 2021 Covid-19 vac­cine sales

Zachary Brennan

Senior Editor

BioN­Tech, Pfiz­er’s rel­a­tive­ly qui­et Ger­man biotech part­ner for its Covid-19 vac­cine, made noise on Tues­day with its earn­ings re­port, pro­ject­ing about €10 bil­lion ($11.5 bil­lion) …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Cal­i­for­nia vot­ers say yes to re­stric­tions around 340B spend­ing

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times